My Personal Therapeutics and Pentavere receive Eureka funding
My Personal Therapeutics, a London-based medtech/digital therapeutics company and Pentavere Research Group, a Canadian-based Artificial Intelligence and data insight company have been awarded Eurkela Collaborative R&D funding for artificial intelligence and quantum technologies. The funding is for a project titled: Utilisation of AI to develop Personalised Treatment Plans for cancer.
Funding totalling £792,000 (Euro 870,000) is co-funded by the UK’s innovation agency, Innovate UK, and Canada’s National Research Council’s Industrial Research Assistant Program, as part of their collaborate R&D programme.
These funds will be used by Pentavere Research Group and My Personal Therapeutics to access Genomics England’s whole genome sequencing lung cancer data set and selectively generate drosophila avatars for high-throughput drug screening. The resulting tumour genomic profile and corresponding drug treatment recommendation data will feed into their AI Personal Discovery Process (PDP) predictive model.
Laura Towart, CEO, My Personal Therapeutics, commented: “This Eureka award will partly fund this ground-breaking collaboration between My Personal Therapeutics, Pentavere and Genomics England towards the development of our rapid personalised cancer therapeutics offering – AI PDP.”
The PDP technology leverages Big Data curated from electronic health records, and genomics to build personalised fruit fly ‘avatars’ that model individual patients at an unprecedented level of complexity. Using robotics, thousands of drugs are screened in combinations to identify drug cocktails designed to target the tumour while preserving the patient’s quality of life. Nearly all combinations incorporate non-cancer drugs, making them less toxic and more affordable. The company says they are integrating AI predictive modelling to enable rapid personalised treatment recommendations.